Evoke Pharma (EVOK) Competitors $4.46 -0.06 (-1.33%) Closing price 10/17/2025 03:59 PM EasternExtended Trading$4.53 +0.07 (+1.46%) As of 10/17/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVOK vs. CVKD, LNAI, DARE, PASG, ENLV, LPTX, ALVR, NNVC, MIRA, and PMNShould you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include Cadrenal Therapeutics (CVKD), Lunai Bioworks (LNAI), Dare Bioscience (DARE), Passage Bio (PASG), Enlivex Therapeutics (ENLV), Leap Therapeutics (LPTX), AlloVir (ALVR), NanoViricides (NNVC), MIRA Pharmaceuticals (MIRA), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry. Evoke Pharma vs. Its Competitors Cadrenal Therapeutics Lunai Bioworks Dare Bioscience Passage Bio Enlivex Therapeutics Leap Therapeutics AlloVir NanoViricides MIRA Pharmaceuticals Promis Neurosciences Evoke Pharma (NASDAQ:EVOK) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment. Do insiders & institutionals believe in EVOK or CVKD? 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 6.1% of Evoke Pharma shares are held by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is EVOK or CVKD more profitable? Cadrenal Therapeutics has a net margin of 0.00% compared to Evoke Pharma's net margin of -42.07%. Evoke Pharma's return on equity of -99.48% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Evoke Pharma-42.07% -99.48% -33.58% Cadrenal Therapeutics N/A -265.37%-196.38% Do analysts rate EVOK or CVKD? Cadrenal Therapeutics has a consensus price target of $32.00, indicating a potential upside of 134.78%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Evoke Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evoke Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger valuation & earnings, EVOK or CVKD? Evoke Pharma has higher revenue and earnings than Cadrenal Therapeutics. Evoke Pharma is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvoke Pharma$10.25M0.68-$5.35M-$2.56-1.74Cadrenal TherapeuticsN/AN/A-$10.65M-$8.88-1.53 Does the media favor EVOK or CVKD? In the previous week, Cadrenal Therapeutics had 4 more articles in the media than Evoke Pharma. MarketBeat recorded 5 mentions for Cadrenal Therapeutics and 1 mentions for Evoke Pharma. Evoke Pharma's average media sentiment score of 0.00 beat Cadrenal Therapeutics' score of -0.43 indicating that Evoke Pharma is being referred to more favorably in the media. Company Overall Sentiment Evoke Pharma Neutral Cadrenal Therapeutics Neutral Which has more risk & volatility, EVOK or CVKD? Evoke Pharma has a beta of -0.1, indicating that its share price is 110% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. SummaryCadrenal Therapeutics beats Evoke Pharma on 9 of the 15 factors compared between the two stocks. Get Evoke Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVOK vs. The Competition Export to ExcelMetricEvoke PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.96M$4.44B$6.13B$10.55BDividend YieldN/A0.88%5.72%4.83%P/E Ratio-1.7410.8585.7827.06Price / Sales0.6821.85612.92132.30Price / CashN/A7.4625.8230.35Price / Book0.944.2712.226.58Net Income-$5.35M-$134.23M$3.33B$276.84M7 Day Performance-4.29%0.32%0.67%-0.72%1 Month Performance-14.56%12.18%6.88%2.16%1 Year Performance-19.06%64.25%58.88%34.63% Evoke Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOKEvoke Pharma0.4565 of 5 stars$4.46-1.3%N/A-19.1%$6.96M$10.25M-1.744Short Interest ↓CVKDCadrenal Therapeutics2.9 of 5 stars$14.06-0.3%$32.00+127.6%-21.0%$28.86MN/A-1.584LNAILunai BioworksN/A$1.24+1.6%N/AN/A$28.28MN/A-0.1620DAREDare Bioscience2.5332 of 5 stars$2.05-0.5%$10.00+387.8%-45.6%$27.77M-$17.70K-0.9630Positive NewsPASGPassage Bio3.0839 of 5 stars$8.52+0.1%$75.67+788.1%-30.4%$27.06MN/A-0.47130Gap UpENLVEnlivex Therapeutics2.6898 of 5 stars$1.16+4.5%$10.00+762.1%-30.3%$26.97MN/A-2.0070LPTXLeap Therapeutics2.8399 of 5 stars$0.62+0.5%$3.38+440.9%-79.4%$25.73MN/A-0.3940Positive NewsAnalyst DowngradeShort Interest ↓Gap UpALVRAlloVirN/A$5.10+7.1%N/A-74.0%$25.72MN/A-0.25110High Trading VolumeNNVCNanoViricides0.8191 of 5 stars$1.44+6.7%N/A+1.4%$25.10MN/A-2.0020Short Interest ↓MIRAMIRA Pharmaceuticals0.3674 of 5 stars$1.32+0.8%N/A+47.3%$24.98MN/A-2.692High Trading VolumePMNPromis Neurosciences3.6303 of 5 stars$0.48+3.9%$4.33+808.5%-55.8%$24.70MN/A-2.275Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies CVKD Alternatives LNAI Alternatives DARE Alternatives PASG Alternatives ENLV Alternatives LPTX Alternatives ALVR Alternatives NNVC Alternatives MIRA Alternatives PMN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVOK) was last updated on 10/20/2025 by MarketBeat.com Staff From Our Partners$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBankrupt to billionaire after retirement?Expert Reveals: The #1 Retirement Play for 2025 "We're Entering the Greatest Energy Bull Market Since the I...Brownstone Research | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
